<b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol

<p>Abstract</p> <p>Background</p> <p>The appropriate level of oxygenation for extremely preterm neonates (<28 weeks' gestation) to maximise the greatest chance of survival, without incurring significant morbidity, remains unknown. Infants exposed to lower levels...

Full description

Bibliographic Details
Main Authors: Schmidt Barbara, Finer Neil, Darlow Brian A, Brocklehurst Peter, Askie Lisa M, Tarnow-Mordi William
Format: Article
Language:English
Published: BMC 2011-01-01
Series:BMC Pediatrics
Online Access:http://www.biomedcentral.com/1471-2431/11/6
_version_ 1819138347166072832
author Schmidt Barbara
Finer Neil
Darlow Brian A
Brocklehurst Peter
Askie Lisa M
Tarnow-Mordi William
author_facet Schmidt Barbara
Finer Neil
Darlow Brian A
Brocklehurst Peter
Askie Lisa M
Tarnow-Mordi William
author_sort Schmidt Barbara
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>The appropriate level of oxygenation for extremely preterm neonates (<28 weeks' gestation) to maximise the greatest chance of survival, without incurring significant morbidity, remains unknown. Infants exposed to lower levels of oxygen (targeting oxygen saturations of <90%) in the first weeks of life are at increased risk of death, cerebral palsy, patent ductus arteriosus, pulmonary vascular resistance and apnoea, whilst those maintained in higher levels of oxygen (targeting oxygen saturations of >90%) have been reported to have greater rates of morbidity including retinopathy of prematurity and chronic lung disease. In order to answer this clinical dilemma reliably, large scale trial evidence is needed.</p> <p>Methods/Design</p> <p>To detect a small but important 4% increase in death or severe disability in survivors, over 5000 neonates would need to be recruited. As extreme prematurity affects 1% of births, such a project undertaken by one trial group would be prohibitively lengthy and expensive. Hence, the Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration has been formed. A prospective meta-analysis (PMA) is one where studies are identified, evaluated, and determined to be eligible before the results of any included studies are known or published, thereby avoiding some of the potential biases inherent in standard, retrospective meta-analyses. This methodology provides the same strengths as a single large-scale multicentre randomised study whilst allowing greater pragmatic flexibility. The NeOProM Collaboration protocol (NCT01124331) has been agreed prior to the results of individual trials being available. This includes pre-specifying the hypotheses, inclusion criteria and outcome measures to be used. Each trial will first publish their respective results as they become available and the combined meta-analytic results, using individual patient data, will be published when all trials are complete. The primary outcome to be assessed is a composite outcome of death or major disability at 18 months - 2 years corrected age. Secondary outcomes include several measures of neonatal morbidity. The size of the combined dataset will allow the effect of the interventions to be explored more reliably with respect to pre-specified patient- and intervention-level characteristics.</p> <p>Discussion</p> <p>Results should be available by 2014.</p>
first_indexed 2024-12-22T11:05:19Z
format Article
id doaj.art-32ad4dbce23a4070bc703681a07cb695
institution Directory Open Access Journal
issn 1471-2431
language English
last_indexed 2024-12-22T11:05:19Z
publishDate 2011-01-01
publisher BMC
record_format Article
series BMC Pediatrics
spelling doaj.art-32ad4dbce23a4070bc703681a07cb6952022-12-21T18:28:20ZengBMCBMC Pediatrics1471-24312011-01-01111610.1186/1471-2431-11-6<b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocolSchmidt BarbaraFiner NeilDarlow Brian ABrocklehurst PeterAskie Lisa MTarnow-Mordi William<p>Abstract</p> <p>Background</p> <p>The appropriate level of oxygenation for extremely preterm neonates (<28 weeks' gestation) to maximise the greatest chance of survival, without incurring significant morbidity, remains unknown. Infants exposed to lower levels of oxygen (targeting oxygen saturations of <90%) in the first weeks of life are at increased risk of death, cerebral palsy, patent ductus arteriosus, pulmonary vascular resistance and apnoea, whilst those maintained in higher levels of oxygen (targeting oxygen saturations of >90%) have been reported to have greater rates of morbidity including retinopathy of prematurity and chronic lung disease. In order to answer this clinical dilemma reliably, large scale trial evidence is needed.</p> <p>Methods/Design</p> <p>To detect a small but important 4% increase in death or severe disability in survivors, over 5000 neonates would need to be recruited. As extreme prematurity affects 1% of births, such a project undertaken by one trial group would be prohibitively lengthy and expensive. Hence, the Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration has been formed. A prospective meta-analysis (PMA) is one where studies are identified, evaluated, and determined to be eligible before the results of any included studies are known or published, thereby avoiding some of the potential biases inherent in standard, retrospective meta-analyses. This methodology provides the same strengths as a single large-scale multicentre randomised study whilst allowing greater pragmatic flexibility. The NeOProM Collaboration protocol (NCT01124331) has been agreed prior to the results of individual trials being available. This includes pre-specifying the hypotheses, inclusion criteria and outcome measures to be used. Each trial will first publish their respective results as they become available and the combined meta-analytic results, using individual patient data, will be published when all trials are complete. The primary outcome to be assessed is a composite outcome of death or major disability at 18 months - 2 years corrected age. Secondary outcomes include several measures of neonatal morbidity. The size of the combined dataset will allow the effect of the interventions to be explored more reliably with respect to pre-specified patient- and intervention-level characteristics.</p> <p>Discussion</p> <p>Results should be available by 2014.</p>http://www.biomedcentral.com/1471-2431/11/6
spellingShingle Schmidt Barbara
Finer Neil
Darlow Brian A
Brocklehurst Peter
Askie Lisa M
Tarnow-Mordi William
<b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
BMC Pediatrics
title <b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
title_full <b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
title_fullStr <b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
title_full_unstemmed <b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
title_short <b>NeOProM: Ne</b>onatal <b>O</b>xygenation <b>Pro</b>spective <b>M</b>eta-analysis Collaboration study protocol
title_sort b neoprom ne b onatal b o b xygenation b pro b spective b m b eta analysis collaboration study protocol
url http://www.biomedcentral.com/1471-2431/11/6
work_keys_str_mv AT schmidtbarbara bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol
AT finerneil bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol
AT darlowbriana bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol
AT brocklehurstpeter bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol
AT askielisam bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol
AT tarnowmordiwilliam bneopromnebonatalbobxygenationbprobspectivebmbetaanalysiscollaborationstudyprotocol